Prognostic relevance of platelet lymphocyte ratio (PLR) in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
Authors:
Open Access
- 7 June 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1367990
Abstract
Objectives: The prognostic relevance of the platelet-to-lymphocyte ratio (PLR) in gastric cancer (GC) patients undergoing immune checkpoint inhibitor (ICI) treatment remains unclear. This meta-analysis aimed to determine the prognostic impact of PLR in this specific patient cohort.Methods: We searched the PubMed, Cochrane Library, CNKI, and EMBASE databases, including literature published up to September 2023, to investigate the prognostic implications of PLR in patients with gastric cancer undergoing immune checkpoint inhibitor therapy. Outcome measures encompassed overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rates (DCR).Results: Nine studies from seven articles comprising 948 eligible patients were selected. The results revealed a significant correlation between elevated PLR and poorer OS and progression-free survival (PFS) (OS: HR 1.67, 95% CI 1.39–2.00, p < 0.001; PFS: HR 1.51, 95% CI 1.29–1.76, p < 0.001). Subgroup analyses were performed to validate the robustness of the results. Moreover, a meta-analysis of four studies investigating the correlation between the PLR in gastric cancer (GC) patients and the objective response rate/disease control rate (ORR/DCR), showed no significant association between the PLR and ORR/DCR (ORR: RR = 1.01, p = 0.960; DCR: RR = 0.96, p = 0.319).Conclusions: This meta-analysis indicates that elevated PLR in GC patients undergoing ICI treatment is significantly linked to worse OS and PFS. Therefore, PLR can serve as a prognostic indicator of post-treatment outcomes in patients with GC receiving ICIs. Further prospective studies are required to assess the reliability of these findings.Systematic review registration: https://inplasy.com/, identifier INPLASY2023120103.Keywords
This publication has 56 references indexed in Scilit:
- The inflammatory burden index: A promising prognostic predictor in patients with locally advanced gastric cancerClinical Nutrition, 2023
- Pretreatment platelet-to-lymphocyte ratio (PLR) as a prognosticating indicator for gastric cancer patients receiving immunotherapyDiscover Oncology, 2022
- Characteristics of gastric cancer around the worldCritical Reviews in Oncology/Hematology, 2022
- Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Inflammatory burden as a prognostic biomarker for cancerClinical Nutrition, 2022
- Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 updateCritical Reviews in Oncology/Hematology, 2022
- Acquired Resistance to Immune Checkpoint InhibitorsCancer Cell, 2020
- The Platelet Lifeline to Cancer: Challenges and OpportunitiesCancer Cell, 2018
- Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studiesCancer Treatment Reviews, 2017
- Inflammation and cancer: An ancient link with novel potentialsInternational Journal of Cancer, 2007